ARAY logo

Accuray Incorporated Stock Price

NasdaqGS:ARAY Community·US$119.0m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 22 Fair Values set on narratives written by author

ARAY Share Price Performance

US$1.02
-0.89 (-46.60%)
US$3.88
Fair Value
US$1.02
-0.89 (-46.60%)
73.7% undervalued intrinsic discount
US$3.88
Fair Value
Price US$1.02
AnalystConsensusTarget US$3.88

ARAY Community Narratives

AnalystConsensusTarget·
Fair Value US$3.88 73.7% undervalued intrinsic discount

Rising Precision Radiotherapy Demand Will Support Stronger Long Term Earnings Power

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US$3.88
73.7% undervalued intrinsic discount
Revenue
4.2% p.a.
Profit Margin
12.91%
Future PE
11.28x
Price in 2028
US$4.89

Trending Discussion

Updated Narratives

ARAY logo

Rising Precision Radiotherapy Demand Will Support Stronger Long Term Earnings Power

Fair Value: US$3.88 73.7% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with excellent balance sheet.

1 Risk
2 Rewards

Accuray Incorporated Key Details

US$450.9m

Revenue

US$311.5m

Cost of Revenue

US$139.4m

Gross Profit

US$158.8m

Other Expenses

-US$19.3m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-0.17
30.93%
-4.28%
226.6%
View Full Analysis

About ARAY

Founded
1990
Employees
990
CEO
Stephen LaNeve
WebsiteView website
www.accuray.com

Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.